KCI requests Developmental Funds in support of: 1) recruitment of new basic and translational investigators;2) innovative projects that bridge several areas of research;and 3) development of Shared Resources (Cores). KCI's Developmental Funds have been used with endorsement of the External Advisory Board and the Senior Leadership of the Cancer Center to enhance the strengths of the current scientific Programs and to increase utilization of the Shared Resources. The Developmental Funds are critical to leverage the support of key Wayne State University stakeholders and local philanthropists. KCI's use of Developmental Funds to support faculty recruitment links with our plan for scientific research investment and supports our continued efforts to grow translational research by increasing interactions among basic scientists and clinicians. The Institute will continue its successful Strategic Research Initiative Grant program and its new Joint Post-Doctoral Training program in order to stimulate projects that have a high potential to go on to program project or SPORE applications. Two new developing Cores are proposed in this application for support from Developmental Funds. The proposed Clinical Imaging Researcii Core promotes imaging in support of cancer detection and therapy and facilitates the integration of functional imaging into routine clinical practice. Finally, the proposed Translational Research Core offers services to develop biochemical, molecular, or cellular assays tailored and validated according to the specific and customized translational research question associated with clinical trials.
Developmental Funds provide support to KCI to: 1) recruit new basic and translational investigators;2) support innovative projects that bridge several areas of research;and 3) support developing Shared Resources (Cores).
|Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294|
|Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562|
|Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :|
|Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :|
|Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017|
|Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008|
|Cheriyan, Vino T; Alsaab, Hashem; Sekhar, Sreeja et al. (2018) A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget 9:29680-29697|
|Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597|
|Dedigama-Arachchige, Pavithra M; Acharige, Nuwan P N; Pflum, Mary Kay H (2018) Identification of PP1-Gadd34 substrates involved in the unfolded protein response using K-BIPS, a method for phosphatase substrate identification. Mol Omics 14:121-133|
|Burl, Rayanne B; Ramseyer, Vanesa D; Rondini, Elizabeth A et al. (2018) Deconstructing Adipogenesis Induced by ?3-Adrenergic Receptor Activation with Single-Cell Expression Profiling. Cell Metab 28:300-309.e4|
Showing the most recent 10 out of 826 publications